Invasive Aspergillosis is primarily treated with which medication?

The primary treatment for Invasive Aspergillosis is Voriconazole. This antifungal medication is specifically indicated due to its superior efficacy against Aspergillus species when compared to other antifungals. Voriconazole has a broad spectrum of activity and works by inhibiting the synthesis of ergosterol, which is an essential component of the fungal cell membrane.

Clinical guidelines and substantial research highlight Voriconazole as the preferred first-line therapy for Invasive Aspergillosis due to its better pharmacokinetics, which provide higher serum and tissue concentrations, and its effectiveness against strains of Aspergillus that may demonstrate resistance to other antifungal agents. Furthermore, Voriconazole has been shown to reduce mortality in patients with this serious fungal infection, making it the drug of choice in clinical settings.

Fluconazole, although effective against various fungal infections, does not have sufficient activity against Aspergillus species. Itraconazole can be used for some non-invasive forms of Aspergillosis but is not recommended as a first-line treatment for invasive cases due to its limited efficacy compared to Voriconazole. Amphotericin B is also an option for severe cases and certain resistant strains, but it is generally reserved for cases where Voriconazole